Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164862 | 1.00 | ALDH1A1 (0.40) | ALDH1A1FFAR2JAK2EGFRHSPA5 | |
| SCHEMBL5219207 | 0.84 | CTSA (0.39) | — | |
| SCHEMBL5219201 | 0.84 | CTSA (0.39) | — | |
| SCHEMBL14541594 | 0.82 | CDK4 (0.34) | ALDH1A1FFAR2HSPA5HSPA2GCK | |
| SCHEMBL5218373 | 0.81 | ALDH1A1 (0.38) | ALDH1A1JAK2EGFRHSPA5GCK | |
| SCHEMBL5218369 | 0.81 | ALDH1A1 (0.38) | ALDH1A1JAK2EGFRHSPA5GCK | |
| SCHEMBL6374179 | 0.81 | TDP1 (0.37) | ALDH1A1FFAR2XBP1CDK4CCND1 | |
| SCHEMBL6374183 | 0.81 | TDP1 (0.37) | ALDH1A1FFAR2XBP1CDK4CCND1 | |
| SCHEMBL4174586 | 0.81 | FDPS (0.44) | ALDH1A1JAK2EGFRSMN1; SMN2TSHR | |
| SCHEMBL4174581 | 0.81 | FDPS (0.44) | ALDH1A1JAK2EGFRSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227600-A1 | 4-(PYRAZINE-2-YL) -PYRROLIDINE -2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| EP-1554274-B1 | 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | GLAXO GROUP LTD (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-7304087-B2 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LIMITED (GB) | 2007-12-04 | — | — | US | disclosed |
| US-7259163-B2 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-21 | — | — | US | disclosed |
| EP-1440069-B1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| EP-1812431-A1 | 4-(PYRAZINE-2-YL)-PYRROLIDINE-2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007039145-A1 | C (2) -HETEROARYLMETHYL-C (4) -PYRAZINYL-2-YL ACYL PYRROLIDINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITIS C VIRUS | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039143-A1 | C (2) -HETEROARYLMETHYL-C (4) -PYRAZIN-2-YL ACYL PYRROLIDINE COMPOUNDS AND THEIR USER FOR TREATING VIRAL INFECTIONS, ESPECIALLY HEPATITICS C (HCV) | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1740582-A1 | ACYL DIHYDRO PYRROLE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-10 | — | — | EP | disclosed |
| US-20060258720-A1 | 1-Acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| US-20050043545-A1 | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | US | disclosed |
| WO-2004076415-A1 | 1- (HETERO)AROYL-PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS ANTI.VIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
| EP-1440069-A1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-28 | — | — | EP | disclosed |
| EP-1440070-A1 | 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-28 | — | — | EP | disclosed |
| EP-1440068-A1 | ACYL DIHYDRO PYRROLE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2004060889-A1 | 5-THIAZOLE SUBSTITUTED 2-PYRROLIDINE-CARBOXYLIC ACIDS | GLAXO GROUP LIMITED (GB) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004009543-A2 | 1-CARBONYL-4-CYANO-PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003037895-A1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037894-A1 | 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037893-A1 | ACYL DIHYDRO PYRROLE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258720-A1 | 1-Acyl-pyrrolidine derivatives for the treatment of viral infections | HAVCR2, LIPC, ACADVL | ALDH1A1 304/4885FFAR2 2826/4885JAK2 510/4885 |
| US-20050043545-A1 | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | NR1H3, NR1H2, NR1I3 | ALDH1A1 234/4885FFAR2 236/4885JAK2 2607/4885 |
| US-20090227600-A1 | 4-(PYRAZINE-2-YL) -PYRROLIDINE -2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, ZC3HAV1L | ALDH1A1 164/4885FFAR2 2071/4885JAK2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.